3 results on '"Barragán N"'
Number of results to display per page
Search Results
2. Influence of oligoclonal IgM specificity in multiple sclerosis disease course.
- Author
-
Villar, L. M., García-Barragán, N., Espiño, M., Roldán, E., Sádaba, M. C., Gómez-Rial, J., González-Porqué, P., and Álvarez-Cermeño, J. C.
- Subjects
- *
IMMUNOGLOBULIN M , *MULTIPLE sclerosis , *MYELIN genes , *B cells , *CELL populations , *IMMUNOGLOBULINS , *PATIENTS - Abstract
Oligoclonal IgM bands (OCMB) against myelin lipids predict an aggressive multiple sclerosis (MS) course. However, the clinical significance of OCMB without lipid specificity, present in other MS patients, remains unknown. We describe here a characterization of these antibodies and study their role in MS progression. Fifty-four MS patients showing CSF-restricted OCMB were included in this study at disease onset and followed-up during 61.1 ± 2.7 months. The specificity of OCMB and the CSF B-cell profile were investigated. A second CSF IgM study was performed in a group of eight patients. Thirty-eight patients showed OCMB against myelin lipids (M+L+) and other sixteen had OCMB lacking this specificity (M+L-). The CD5+ B cell subpopulation, responsible for most persistent IgM responses, was considerably higher in M+L+ than in M+L- patients (3.3 ± 0.6% versus 0.8 ±0.2, P =0.009). In addition, M+L+ bands persisted during disease course, while M+L- disappeared during follow-up. M+L+ patients suffered more relapses (4.2 ± 0.6 versus 1.6 ± 0.3, P = 0.002) and reached higher disability (EDSS score of 2.2 ± 0.2 versus 1.2 ± 0.2, P = 0.02) than M+L- group. These data corroborate that anti-lipid OCMB associate with an aggressive MS course and show that OCMB that do not recognize myelin lipids represent a transient immune response related to a more benign disease course. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
3. Five microRNAs in Serum Are Able to Differentiate Breast Cancer Patients From Healthy Individuals
- Author
-
Andrea Feliciano, Lucila González, Yoelsis Garcia-Mayea, Cristina Mir, Mireia Artola, Nieves Barragán, Remedios Martín, Anna Altés, Josep Castellvi, Sergi Benavente, Santiago Ramón y Cajal, Martín Espinosa-Bravo, Javier Cortés, Isabel T. Rubio, Matilde E. LLeonart, Institut Català de la Salut, [Feliciano A, González L, Garcia-Mayea Y, Mir C, Castellvi J, Benavente S, Ramón Y Cajal S] Grup de Recerca biomèdica amb cel·lules mare del càncer, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Artola M, Barragán N] Primary Care Center CAP-Vallcarca-Sant Gervasi, Barcelona, Spain. [Espinosa-Bravo M] Unitat de Patologia Mamària, Vall d'Hebron Hospital Universitari, Barcelona, Spain. [Cortés J] Institute of Breast Cancer, Quiron Group, Barcelona, Spain. Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. [LLeonart ME] Grup de Recerca biomèdica amb cel·lules mare del càncer, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Spanish Biomedical Research Network Center in Oncology, Madrid, Spain, and Vall d'Hebron Barcelona Hospital Campus
- Subjects
Serum ,0301 basic medicine ,Oncology ,Cancer Research ,medicine.medical_specialty ,diagnosis ,Neoplasms::Neoplasms by Site::Breast Neoplasms [DISEASES] ,Otros calificadores::/diagnóstico [Otros calificadores] ,lcsh:RC254-282 ,03 medical and health sciences ,Breast cancer ,breast cancer ,0302 clinical medicine ,Downregulation and upregulation ,Internal medicine ,Diagnosis ,microRNA ,Nucleic Acids, Nucleotides, and Nucleosides::Antisense Elements (Genetics)::RNA, Antisense::MicroRNAs::Circulating MicroRNA [CHEMICALS AND DRUGS] ,nucleótidos y nucleósidos de ácidos nucleicos::elementos antisentido (genética)::ARN antiparalelo::microARN::microARN circulante [COMPUESTOS QUÍMICOS Y DROGAS] ,Other subheadings::/diagnosis [Other subheadings] ,Medicine ,Clinical significance ,Mama - Càncer - Diagnòstic ,Original Research ,MicroARN ,neoplasias::neoplasias por localización::neoplasias de la mama [ENFERMEDADES] ,biology ,business.industry ,Incidence (epidemiology) ,CD44 ,Cancer ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Prognosis ,medicine.disease ,microRNAs ,Circulating MicroRNA ,030104 developmental biology ,030220 oncology & carcinogenesis ,biology.protein ,prognosis ,business ,serum - Abstract
Càncer de mama; Diagnòstic; Sèrum Cáncer de mama; Diagnóstico; Suero Breast cancer; Diagnosis; Serum Breast cancer is the cancer with the most incidence and mortality in women. microRNAs are emerging as novel prognosis/diagnostic tools. Our aim was to identify a serum microRNA signature useful to predict cancer development. We focused on studying the expression levels of 30 microRNAs in the serum of 96 breast cancer patients vs. 92 control individuals. Bioinformatic studies provide a microRNA signature, designated as a predictor, based on the expression levels of five microRNAs. Then, we tested the predictor in a group of 60 randomly chosen women. Lastly, a proteomic study unveiled the overexpression and downregulation of proteins differently expressed in the serum of breast cancer patients vs. that of control individuals. Twenty-six microRNAs differentiate cancer tissue from healthy tissue, and 16 microRNAs differentiate the serum of cancer patients from that of the control group. The tissue expression of miR-99a, miR-497, miR-362, and miR-1274, and the serum levels of miR-141 correlated with patient survival. Moreover, the predictor consisting of miR-125b, miR-29c, miR-16, miR-1260, and miR-451 was able to differentiate breast cancer patients from controls. The predictor was validated in 20 new cases of breast cancer patients and tested in 60 volunteer women, assigning 11 out of 60 women to the cancer group. An association of low levels of miR-16 with a high content of CD44 protein in serum was found. Circulating microRNAs in serum can represent biomarkers for cancer prediction. Their clinical relevance and the potential use of the predictor here described are discussed. This work was supported by ISCIII (Instituto de Salud Carlos III) Ref. FIS PI15/01262, co-financed by the European Regional Development Fund (ERDF) and AECC Project GEC Ref. GC16173720CARR (ML). AF, YG-M, and CM were granted with P-FIS, VHIR, and iP-FIS fellowships, respectively.
- Published
- 2020
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.